問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Medical University Hospital

Division of Thoracic Medicine

List

83Cases

2017-09-30 - 2022-09-30

Phase I

A Phase 1 Study of HLX06, a Fully Human Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients with Advanced Solid Tumors Refractory to Standard Therapy

  • Condition/Disease

    Patients with Advanced Solid Tumors Refractory to Standard Therapy

  • Test Drug

    HLX06

Participate Sites
3Sites

Terminated3Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2021-07-21 - 2023-03-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2014-08-01 - 2021-11-19

Phase III

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MEDI4736

Participate Sites
6Sites

Terminated6Sites

2014-08-01 - 2017-12-31

Phase III

A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)

  • Condition/Disease

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    MEDI4736; Tremelimumab

Participate Sites
9Sites

Terminated9Sites

2021-07-27 - 2025-06-30

Phase II

A Phase II Study to Evaluate the Efficacy and Safety of FB825 in Adult Patients with Moderate-to-severe Allergic Asthma

  • Condition/Disease

    Allergic Asthma

  • Test Drug

    FB825

Participate Sites
17Sites

Not yet recruiting5Sites

Recruiting12Sites

2011-04-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2023-04-01 - 2025-12-31

Phase I/II

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    Gen1042

Participate Sites
7Sites

Recruiting7Sites

2009-05-01 - 2011-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-03-10 - 2026-05-21

Phase I

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    CLN-081

Participate Sites
7Sites

Recruiting7Sites

2023-08-01 - 2025-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB